Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

Price$13.75

Value ScoreC

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)1.90%

Price vs S&P 500 (4W)4.18%

VGM Score59.09

Market Capitalization$4.39B

P/E Ratio (Annual)60.88x

All Metrics

P/CF (Annual)12.90x

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)285.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)10.92%

Cash Flow / Share (Quarterly)$0.59

Price vs S&P 500 (YTD)0.97%

Gross Margin (TTM)38.66%

Net Profit Margin (TTM)4.01%

EPS (TTM)$0.37

10-Day Avg Trading Volume1.66M

EPS Excl Extra (TTM)$0.37

Revenue Growth (5Y)8.66%

EPS (Annual)$0.22

ROI (Annual)-3.09%

Gross Margin (Annual)36.88%

Net Profit Margin (5Y Avg)-2.13%

Cash / Share (Quarterly)$0.62

P/E Basic Excl Extra (TTM)35.92x

Revenue Growth QoQ (YoY)3.90%

EPS Growth (5Y)-18.37%

P/E Normalized (Annual)60.88x

ROA (Last FY)1.96%

Revenue Growth TTM (YoY)7.62%

EBITD / Share (TTM)$1.97

ROE (5Y Avg)-118.23%

Operating Margin (TTM)14.30%

Cash Flow / Share (Annual)$0.72

P/B Ratio221.76x

P/B Ratio (Quarterly)140.74x

Net Income / Employee (Annual)$8,500

EV / Revenue (TTM)2.24x

Net Interest Coverage (TTM)1.60x

ROA (TTM)3.43%

EPS Growth QoQ (YoY)403.46%

EV / EBITDA (TTM)10.62x

EPS Incl Extra (Annual)$0.22

Current Ratio (Annual)2.17x

Quick Ratio (Quarterly)1.52x

3-Month Avg Trading Volume2.31M

52-Week Price Return91.77%

EV / Free Cash Flow (Annual)30.22x

P/E Incl Extra (TTM)35.92x

Revenue / Employee (TTM)$358,300

Tangible BV / Share (Quarterly)$0.05

P/S Ratio (Annual)1.45x

Asset Turnover (Annual)0.82x

52-Week High$15.42

Operating Margin (5Y Avg)6.70%

EPS Excl Extra (Annual)$0.22

CapEx CAGR (5Y)11.55%

Tangible BV CAGR (5Y)-64.27%

26-Week Price Return9.82%

Quick Ratio (Annual)1.42x

13-Week Price Return3.70%

Total Debt / Equity (Annual)136.58x

Current Ratio (Quarterly)2.47x

Enterprise Value$6.82B

Revenue / Share Growth (5Y)-7.03%

Asset Turnover (TTM)0.86x

Book Value / Share Growth (5Y)-51.99%

Revenue / Employee (Annual)$355,100

Inventory Turnover (Annual)3.13x

Pretax Margin (Annual)4.61%

Cash / Share (Annual)$0.90

3-Month Return Std Dev36.51%

Gross Margin (5Y Avg)36.59%

Net Income / Employee (TTM)$14,400

EBITDA CAGR (5Y)13.59%

EBITDA Interim CAGR (5Y)12.77%

ROE (Last FY)-424.61%

Net Interest Coverage (Annual)1.75x

EPS Basic Excl Extra (Annual)$0.22

P/FCF (TTM)18.54x

Receivables Turnover (TTM)3.76x

EV / Free Cash Flow (TTM)36.25x

Total Debt / Equity (Quarterly)136.58x

EPS Incl Extra (TTM)$0.37

Receivables Turnover (Annual)3.61x

ROI (TTM)-2.80%

P/S Ratio (TTM)1.44x

Pretax Margin (5Y Avg)-1.75%

Revenue / Share (Annual)$9.29

Tangible BV / Share (Annual)$0.05

Forward P/E12.50x

Free OCF CAGR (5Y)-6.32%

Price vs S&P 500 (52W)67.41%

P/E Ratio (TTM)35.92x

Year-to-Date Return9.13%

5-Day Price Return6.59%

EPS Normalized (Annual)$0.22

ROA (5Y Avg)-1.39%

Net Profit Margin (Annual)2.39%

Month-to-Date Return4.40%

Cash Flow / Share (TTM)$1.76

EBITD / Share (Annual)$1.90

Operating Margin (Annual)13.05%

LT Debt / Equity (Annual)122.72x

P/CF (TTM)14.34x

ROI (5Y Avg)-3.29%

P/E Excl Extra (TTM)35.92x

LT Debt / Equity (Quarterly)122.72x

EPS Basic Excl Extra (TTM)$0.37

P/TBV (Quarterly)285.99x

P/B Ratio (Annual)140.74x

Inventory Turnover (TTM)3.01x

Pretax Margin (TTM)5.97%

Book Value / Share (Annual)$0.04

Price vs S&P 500 (13W)-4.56%

Net Margin Growth (5Y)-12.16%

Beta1.32x

P/FCF (Annual)19.44x

Revenue / Share (TTM)$9.26

ROE (TTM)-34.88%

52-Week Low$7.07

vGradeC

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.27est. 0.17

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.09

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$13.75
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Amneal Pharmaceuticals develops and manufactures pharmaceutical products across three segments: Affordable Medicines (generics and essential drugs), Specialty (branded pharmaceuticals for CNS and endocrine disorders), and AvKARE (government pharmaceutical distribution). Operating in the U.S., India, and Ireland, the company serves diverse market segments including cost-conscious patients, specialty therapy areas, and government agencies.